Go Pro
→ Three companies about to leapfrog Nvidia [And transform the entire industry] (From Eagle Publishing) (Ad)tc pixel Free BACK Stock Alerts

IMAC (BACK) Competitors

IMAC logo
$0.0005 0.00 (0.00%)
As of 09/2/2026
Compare

BACK vs. AONCW, BTSGU, LFMDP, NIVFW, and PIIIW

Should you buy IMAC stock or one of its competitors? IMAC's main competitors and comparable companies include American Oncology Network (AONCW), BrightSpring Health Services (BTSGU), LifeMD (LFMDP), NewGenIvf Group (NIVFW), and P3 Health Partners (PIIIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare providers & services" industry.

How does IMAC compare to American Oncology Network?

American Oncology Network (NASDAQ:AONCW) and IMAC (NASDAQ:BACK) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

In the previous week, IMAC had 2 more articles in the media than American Oncology Network. MarketBeat recorded 2 mentions for IMAC and 0 mentions for American Oncology Network. IMAC's average media sentiment score of 0.42 beat American Oncology Network's score of 0.00 indicating that IMAC is being referred to more favorably in the news media.

Company Overall Sentiment
American Oncology Network Neutral
IMAC Neutral

5.8% of IMAC shares are owned by institutional investors. 12.3% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
American Oncology NetworkN/A N/A N/A
IMAC N/A N/A -325.44%

American Oncology Network has higher revenue and earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
American Oncology Network$1.34BN/AN/AN/AN/A
IMAC$72.05K0.03-$9.42M-$3.12N/A

Summary

IMAC beats American Oncology Network on 4 of the 6 factors compared between the two stocks.

How does IMAC compare to BrightSpring Health Services?

BrightSpring Health Services (NASDAQ:BTSGU) and IMAC (NASDAQ:BACK) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BrightSpring Health Services
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
IMAC
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

5.8% of IMAC shares are held by institutional investors. 12.3% of IMAC shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

BrightSpring Health Services has higher revenue and earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BrightSpring Health Services$14.37BN/AN/AN/AN/A
IMAC$72.05K0.03-$9.42M-$3.12N/A

In the previous week, IMAC had 2 more articles in the media than BrightSpring Health Services. MarketBeat recorded 2 mentions for IMAC and 0 mentions for BrightSpring Health Services. IMAC's average media sentiment score of 0.42 beat BrightSpring Health Services' score of 0.00 indicating that IMAC is being referred to more favorably in the news media.

Company Overall Sentiment
BrightSpring Health Services Neutral
IMAC Neutral

Company Net Margins Return on Equity Return on Assets
BrightSpring Health ServicesN/A N/A N/A
IMAC N/A N/A -325.44%

Summary

IMAC beats BrightSpring Health Services on 4 of the 7 factors compared between the two stocks.

How does IMAC compare to LifeMD?

LifeMD (NASDAQ:LFMDP) and IMAC (NASDAQ:BACK) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

In the previous week, IMAC had 2 more articles in the media than LifeMD. MarketBeat recorded 2 mentions for IMAC and 0 mentions for LifeMD. IMAC's average media sentiment score of 0.42 beat LifeMD's score of 0.00 indicating that IMAC is being referred to more favorably in the news media.

Company Overall Sentiment
LifeMD Neutral
IMAC Neutral

Company Net Margins Return on Equity Return on Assets
LifeMDN/A N/A N/A
IMAC N/A N/A -325.44%

LifeMD has higher revenue and earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LifeMD$191.59MN/AN/AN/AN/A
IMAC$72.05K0.03-$9.42M-$3.12N/A

5.8% of IMAC shares are held by institutional investors. 12.3% of IMAC shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

IMAC beats LifeMD on 4 of the 6 factors compared between the two stocks.

How does IMAC compare to NewGenIvf Group?

IMAC (NASDAQ:BACK) and NewGenIvf Group (NASDAQ:NIVFW) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

5.8% of IMAC shares are owned by institutional investors. 12.3% of IMAC shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, IMAC had 1 more articles in the media than NewGenIvf Group. MarketBeat recorded 2 mentions for IMAC and 1 mentions for NewGenIvf Group. IMAC's average media sentiment score of 0.42 beat NewGenIvf Group's score of 0.00 indicating that IMAC is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IMAC
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
NewGenIvf Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

NewGenIvf Group has higher revenue and earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$72.05K0.03-$9.42M-$3.12N/A
NewGenIvf Group$4.73MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
IMACN/A N/A -325.44%
NewGenIvf Group N/A N/A N/A

Summary

IMAC beats NewGenIvf Group on 4 of the 6 factors compared between the two stocks.

How does IMAC compare to P3 Health Partners?

IMAC (NASDAQ:BACK) and P3 Health Partners (NASDAQ:PIIIW) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

Company Net Margins Return on Equity Return on Assets
IMACN/A N/A -325.44%
P3 Health Partners N/A N/A N/A

P3 Health Partners has higher revenue and earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$72.05K0.03-$9.42M-$3.12N/A
P3 Health Partners$1.50BN/AN/AN/AN/A

5.8% of IMAC shares are owned by institutional investors. 12.3% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, IMAC had 2 more articles in the media than P3 Health Partners. MarketBeat recorded 2 mentions for IMAC and 0 mentions for P3 Health Partners. P3 Health Partners' average media sentiment score of 0.99 beat IMAC's score of 0.42 indicating that P3 Health Partners is being referred to more favorably in the news media.

Company Overall Sentiment
IMAC Neutral
P3 Health Partners Positive

Summary

IMAC and P3 Health Partners tied by winning 3 of the 6 factors compared between the two stocks.

Get IMAC News Delivered to You Automatically

Sign up to receive the latest news and ratings for BACK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BACK vs. The Competition

Export
MetricIMACHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2K$9.97B$7.26B$12.73B
Dividend YieldN/A2.56%2.53%8.86%
P/E Ratio0.0034.83273.3025.25
Price / Sales0.034.88618.1597.66
Price / CashN/A120.9077.8252.26
Price / Book0.003.9812.896.14
Net Income-$9.42M$310.54M$3.47B$349.01M
7 Day PerformanceN/A0.74%0.53%-0.31%
1 Month PerformanceN/A0.11%5.64%0.64%
1 Year PerformanceN/A15.75%25.31%14.83%

IMAC Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BACK
IMAC
N/A$0.00
flat		N/AN/A$2K$72.05KN/A180
AONCW
American Oncology Network
N/A$0.00
flat		N/AN/A$0.00$1.34BN/A1,525
BTSGU
BrightSpring Health Services
N/A$202.19
flat		N/A+139.2%$0.00$14.37BN/A35,000
LFMDP
LifeMD
N/A$23.28
flat		N/A-0.5%$0.00$191.59MN/A230
NIVFW
NewGenIvf Group
N/A$0.02
flat		N/A-18.9%$0.00$4.73MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BACK) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
The 2026 beginners Guide to Gold IRAs
Gold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...
Goldco Direct, LLC | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Are you leaving Social Security money on the table?
Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....
Money Pickle | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel